FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316928118> ?p ?o ?g. }

• W4316928118 endingPage "1945" @default.
• W4316928118 startingPage "1945" @default.
• W4316928118 abstract "To preliminarily evaluate the efficacy and safety of pancreatic intra-arterial infusion chemotherapy (PAIC) with nab-paclitaxel in patients with advanced pancreatic carcinoma.Fifteen patients with advanced pancreatic carcinoma received monthly, inpatient, 3-h, continuous PAIC of nab-paclitaxel at 180 mg/m2, combined with 60 mg oral tegafur gimeracil oteracil potassium capsule for 2 weeks. The therapeutic courses were repeated every 4 weeks. All patients had a preliminary diagnosis based on clinical symptoms, imaging data (computed tomography or magnetic resonance imaging or positron emission tomography/computed tomography), and tumor markers. The adverse effects, clinical benefit response (CBR), objective response rate (ORR), median progression free survival (mPFS), and median overall survival (mOS) were monitored.Fifteen patients with advanced pancreatic carcinoma were enrolled in this study, including 10 male and 5 female patients. The mean age at the time of treatment was 66.3 years (53-84 years). A total of 49 cycles of PAIC (mean = 3.27 cycles/patient) were performed. The most common treatment-related toxicities were alopecia, diarrhea, and nausea/vomiting. No procedure-related complications were observed. The longest overall survival observed was 22 months and the maximum number of treatments for the same patient was six cycles. PAIC contributed a high rate (13/15 [86.67%]) and fast (10/15 [66.67%]) easement of pain, with apparent symptom relief within 24 h, especially local pain symptom. The pain anesis rate was 13 (86.67%). CBR was achieved in 13 (86.67%) patients (95%CI [59.54,98.34]). ORR was achieved in four (26.67%) patients (95%CI [7.79,55.10]). Disease Control Rate was achieved in 14 (93.33%) patients. The mPFS was 5.22 months (interquartile range [IQR], 4.27-7.85 months). The mOS was 8.97 months (IQR, 5.65-13.70 months).In this study, the dose of the chemotherapeutics and the schedule of the transcatheter pancreatic arterial chemotherapy perfusion were shown to be safe, well-tolerated, and effective for the relief of clinical symptoms and CBR. These advantages can quickly establish the treatment belief and improve patient quality of life. This regimen requires further investigation in patients with advanced pancreatic carcinoma." @default.
• W4316928118 created "2023-01-18" @default.
• W4316928118 creator A5010465278 @default.
• W4316928118 creator A5019288987 @default.
• W4316928118 creator A5024620764 @default.
• W4316928118 creator A5030921116 @default.
• W4316928118 creator A5073291175 @default.
• W4316928118 date "2022-01-01" @default.
• W4316928118 modified "2023-10-18" @default.
• W4316928118 title "Pancreatic intra-arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma: A pilot study" @default.
• W4316928118 cites W1931508686 @default.
• W4316928118 cites W1996102042 @default.
• W4316928118 cites W2004445606 @default.
• W4316928118 cites W2008907131 @default.
• W4316928118 cites W2026859755 @default.
• W4316928118 cites W2036449594 @default.
• W4316928118 cites W2046231757 @default.
• W4316928118 cites W2081400319 @default.
• W4316928118 cites W2101547731 @default.
• W4316928118 cites W2119686162 @default.
• W4316928118 cites W2135352785 @default.
• W4316928118 cites W2139248078 @default.
• W4316928118 cites W2143463252 @default.
• W4316928118 cites W2472707660 @default.
• W4316928118 cites W2576198513 @default.
• W4316928118 cites W2746929417 @default.
• W4316928118 cites W2766756891 @default.
• W4316928118 cites W2768095276 @default.
• W4316928118 cites W2771616157 @default.
• W4316928118 cites W2794698538 @default.
• W4316928118 cites W2845771753 @default.
• W4316928118 cites W2884778295 @default.
• W4316928118 cites W2897589691 @default.
• W4316928118 cites W2923447254 @default.
• W4316928118 cites W2954483101 @default.
• W4316928118 cites W2972641230 @default.
• W4316928118 cites W2989326204 @default.
• W4316928118 cites W2999417355 @default.
• W4316928118 cites W3010913070 @default.
• W4316928118 cites W3096053571 @default.
• W4316928118 cites W3098634978 @default.
• W4316928118 cites W3157927756 @default.
• W4316928118 cites W3201533818 @default.
• W4316928118 cites W4211253487 @default.
• W4316928118 doi "https://doi.org/10.4103/jcrt.jcrt_819_22" @default.
• W4316928118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36647954" @default.
• W4316928118 hasPublicationYear "2022" @default.
• W4316928118 type Work @default.
• W4316928118 citedByCount "1" @default.
• W4316928118 countsByYear W43169281182023 @default.
• W4316928118 crossrefType "journal-article" @default.
• W4316928118 hasAuthorship W4316928118A5010465278 @default.
• W4316928118 hasAuthorship W4316928118A5019288987 @default.
• W4316928118 hasAuthorship W4316928118A5024620764 @default.
• W4316928118 hasAuthorship W4316928118A5030921116 @default.
• W4316928118 hasAuthorship W4316928118A5073291175 @default.
• W4316928118 hasBestOaLocation W43169281181 @default.
• W4316928118 hasConcept C126322002 @default.
• W4316928118 hasConcept C126838900 @default.
• W4316928118 hasConcept C141071460 @default.
• W4316928118 hasConcept C197934379 @default.
• W4316928118 hasConcept C2776283816 @default.
• W4316928118 hasConcept C2776694085 @default.
• W4316928118 hasConcept C2777299880 @default.
• W4316928118 hasConcept C2777546739 @default.
• W4316928118 hasConcept C2778764654 @default.
• W4316928118 hasConcept C2779802037 @default.
• W4316928118 hasConcept C2780580376 @default.
• W4316928118 hasConcept C2780852908 @default.
• W4316928118 hasConcept C2780955771 @default.
• W4316928118 hasConcept C71924100 @default.
• W4316928118 hasConcept C90924648 @default.
• W4316928118 hasConceptScore W4316928118C126322002 @default.
• W4316928118 hasConceptScore W4316928118C126838900 @default.
• W4316928118 hasConceptScore W4316928118C141071460 @default.
• W4316928118 hasConceptScore W4316928118C197934379 @default.
• W4316928118 hasConceptScore W4316928118C2776283816 @default.
• W4316928118 hasConceptScore W4316928118C2776694085 @default.
• W4316928118 hasConceptScore W4316928118C2777299880 @default.
• W4316928118 hasConceptScore W4316928118C2777546739 @default.
• W4316928118 hasConceptScore W4316928118C2778764654 @default.
• W4316928118 hasConceptScore W4316928118C2779802037 @default.
• W4316928118 hasConceptScore W4316928118C2780580376 @default.
• W4316928118 hasConceptScore W4316928118C2780852908 @default.
• W4316928118 hasConceptScore W4316928118C2780955771 @default.
• W4316928118 hasConceptScore W4316928118C71924100 @default.
• W4316928118 hasConceptScore W4316928118C90924648 @default.
• W4316928118 hasIssue "7" @default.
• W4316928118 hasLocation W43169281181 @default.
• W4316928118 hasLocation W43169281182 @default.
• W4316928118 hasOpenAccess W4316928118 @default.
• W4316928118 hasPrimaryLocation W43169281181 @default.
• W4316928118 hasRelatedWork W2031311309 @default.
• W4316928118 hasRelatedWork W2041128529 @default.
• W4316928118 hasRelatedWork W2318010323 @default.
• W4316928118 hasRelatedWork W2338996806 @default.
• W4316928118 hasRelatedWork W2411848747 @default.
• W4316928118 hasRelatedWork W3044463414 @default.

• next